AD GABA Receptor and Excitotoxicity Therapy Companies

📖 Wiki Page

company1138 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_gaba_receptor_exc["AD GABA Receptor and Excitotoxicity Therapy Comp"] style companies_ad_gaba_receptor_exc fill:#4fc3f7,stroke:#333,color:#000 companies_ad_gaba_re_0["Scientific Rationale"] companies_ad_gaba_receptor_exc -->|"includes"| companies_ad_gaba_re_0 style companies_ad_gaba_re_0 fill:#81c784,stroke:#333,color:#000 companies_ad_gaba_re_1["GABA-A Receptor Positive Allosteric Modulators"] companies_ad_gaba_receptor_exc -->|"includes"| companies_ad_gaba_re_1 style companies_ad_gaba_re_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_gaba_re_2["Sage Therapeutics"] companies_ad_gaba_receptor_exc -->|"includes"| companies_ad_gaba_re_2 style companies_ad_gaba_re_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_gaba_re_3["Supernus Pharmaceuticals"] companies_ad_gaba_receptor_exc -->|"includes"| companies_ad_gaba_re_3 style companies_ad_gaba_re_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_gaba_re_4["Other GABA-A Modulator Developers"] companies_ad_gaba_receptor_exc -->|"includes"| companies_ad_gaba_re_4 style companies_ad_gaba_re_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_gaba_re_5["Glutamate Transporter Enhancers"] companies_ad_gaba_receptor_exc -->|"includes"| companies_ad_gaba_re_5 style companies_ad_gaba_re_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category page catalogs companies developing GABA receptor modulators, glutamate transporter enhancers, NMDA antagonists, AMPA modulators, and related excitotoxicity therapies for Alzheimer's disease (AD). These approaches target the balance between inhibitory (GABAergic) and excitatory (glutamatergic) neurotransmission, which becomes dysregulated in AD pathology.

Scientific Rationale

Excitotoxicity is a key pathological process in AD, where excessive glutamate signaling leads to neuronal damage through overactivation of NMDA and AMPA receptors. This can occur through:

Elevated glutamate levels in the synaptic cleft
Dysfunctional glutamate transporters (EAAT1/EAAT2) leading to reduced glutamate clearance
Hyperexcitability of NMDA receptors
Calcium dysregulation through ionotropic glutamate receptors

GABAergic dysfunction in AD contributes to:

Impaired synaptic inhibition and network hypersynchrony
Seizure activity in some AD patients
Cognitive deficits related to excitation-inhibition imbalance
Accelerated tau pathology propagation

Companies in this space aim to restore the excitation-inhibition balance through multiple mechanisms[@forss2023][@liu2022][@green2018].

GABA-A Receptor Positive Allosteric Modulators

Sage Therapeutics

Website: [Sage Therapeutics](https://www.sagerx.com/)

| Attribute | Details |
|-----------|---------|
| Focus | GABA-A receptor neurosteroid modulators |
| Lead Candidate | SAGE-718 (Navoximod) |
| Indication | Alzheimer's disease (cognitive impairment) |
| Stage | Phase 2 |
| Mechanism | NMDA receptor antagonist (not GABA-A) |

SAGE-718 (Navoximod): An IDO1 inhibitor with NMDA receptor antagonist properties. While primarily an immunomodulatory candidate for depression, SAGE-718 has shown cognitive benefits in AD preclinical models through NMDA modulation.

SAGE-324 (Ganaxolone): A GABA-A receptor positive allosteric modulator. Originally developed for epilepsy and postpartum depression, ganaxolone is being evaluated for AD-related cognitive impairment due to its GABA-enhancing neuroprotective effects.

Clinical Status: SAGE-324 completed Phase 2 trials for essential tremor with safety data supporting CNS development. SAGE-718 in Phase 2 for AD cognitive impairment.

Relevance to AD:

Enhanced GABAergic signaling reduces excitotoxicity
Neuroprotective effects through GABA-A receptor activation
Potential for reducing network hypersynchrony in AD

Supernus Pharmaceuticals

Website: [Supernus Pharmaceuticals](https://www.supernus.com/)

| Attribute | Details |
|-----------|---------|
| Focus | AMPA and GABA modulators |
| Lead Candidate | SPN-820 |
| Indication | Treatment-resistant depression, AD cognitive impairment |
| Stage | Phase 2 |
| Mechanism | AMPA receptor modulator |

SPN-820: An AMPA receptor modulator being developed for treatment-resistant depression. AMPA modulation enhances synaptic plasticity and may provide cognitive benefits in AD through:

Increased AMPA receptor trafficking
Enhanced long-term potentiation (LTP)
Improved memory consolidation

Relevance to AD: AMPA modulation represents a novel approach beyond NMDA-focused strategies, with potential for cognitive enhancement without the dissociative effects of ketamine.

Other GABA-A Modulator Developers

| Company | Candidate | Stage | Notes |
|---------|-----------|-------|-------|
| Biohaven | Various GABA-A PAMs | Discovery | Expanding CNS pipeline post-Pfizer acquisition |
| Cerevel | CVL-231 | Phase 2 | Kv7 opener, also modulates GABA |
| Zymeworks |ZY-OGD-01 | Preclinical | GABA-A selective PAM |

Glutamate Transporter Enhancers

Glutamate transporters (EAAT1/EAAT2) clear glutamate from the synaptic cleft. Reduced transporter function leads to excitotoxicity in AD[@liu2022].

AstraZeneca

Website: [AstraZeneca](https://www.astrazeneca.com/)

| Attribute | Details |
|-----------|---------|
| Focus | EAAT2 enhancers |
| Lead Candidates | Various small molecules |
| Indication | Alzheimer's disease, ALS |
| Stage | Discovery/Preclinical |
| Mechanism | Glutamate transporter (EAAT2) enhancement |

Research Focus: AstraZeneca has explored compounds that enhance glutamate transporter function to reduce extracellular glutamate levels and prevent excitotoxic neuronal damage.

Relevance to AD:

EAAT2 dysfunction observed in AD brain tissue
Enhancing glutamate clearance reduces excitotoxicity
Potential for disease-modifying effects

Daiichi Sankyo

Website: [Daiichi Sankyo](https://www.daiichisankyo.com/)

| Attribute | Details |
|-----------|---------|
| Focus | Glutamate transporter modulators |
| Lead Candidates | Multiple programs |
| Stage | Discovery |
| Mechanism | EAAT1/EAAT2 modulation |

Aevi Genomic Medicine / Others

| Company | Target | Stage | Notes |
|---------|--------|-------|-------|
| EAAT modulators | Multiple | Preclinical | Academic/industry collaborations |

NMDA Receptor Antagonists for Neuroprotection

Traditional NMDA antagonists (memantine) provide modest benefits in AD. Newer approaches aim for more precise modulation[@green2018].

Forest Laboratories / Allergan (Acquired by AbbVie)

Memantine (Namenda) represents the approved NMDA antagonist approach:

Moderate benefits in moderate-to-severe AD
Well-tolerated with minimal psychotomimetic effects
Limited disease-modifying potential

Newer NMDA Approaches

| Company | Candidate | Approach | Stage |
|---------|-----------|----------|-------|
| relmada | REL-1017 | NMDA channel blocker | Phase 3 (depression) |
| Naurex (acquired) | GLYX-13 | Partial agonist | Phase 2 |

Merck (MSD)

Website: [Merck](https://www.merck.com/)

| Attribute | Details |
|-----------|---------|
| Focus | NMDA subunit-selective antagonists |
| Approach | GluN2A-selective targeting |
| Stage | Discovery |
| Relevance | More targeted neuroprotection |

AMPA Receptor Modulators for Synaptic Plasticity

AMPA receptor modulators enhance synaptic plasticity and may improve cognitive function in AD[@ward2019].

Supernus Pharmaceuticals

As detailed above, SPN-820 is an AMPA modulator with potential cognitive benefits.

Additional AMPA Programs

| Company | Candidate | Stage | Notes |
|---------|---------|-------|-------|
| Taked | Various | Preclinical | Japanese CNS pipeline |
| Mitsubishi Tanabe | MT-381 | Discovery | AMPA modulator |

Pipeline Summary

| Approach | Companies | Stage | Promise |
|----------|----------|-------|---------|
| GABA-A PAMs | Sage, Biohaven, Cerevel | Phase 1-2 | High (proven safety) |
| AMPA Modulators | Supernus, Takeda | Phase 2 | Moderate-High |
| Glutamate Transporters | AstraZeneca, Daiichi | Discovery | Moderate |
| NMDA Antagonists | Forest/AbbVie, Relmada | Approved/Phase 3 | Moderate |
| EAAT Enhancers | Multiple academic | Preclinical | Moderate |

Scientific Rationale for AD

GABAergic Deficits in AD

Reduced GABAergic Neurons: GABAergic interneurons are vulnerable in AD, leading to disinhibition

Network Hypersynchrony: Reduced inhibition contributes to epileptiform activity in some AD patients

Cognitive Impairment: Excitation-inhibition imbalance disrupts working memory

Tau Pathology: GABA dysfunction may accelerate tau propagation

Excitotoxicity Mechanisms

Glutamate Accumulation: Reduced transporter function leads to toxic glutamate levels

Calcium Overload: NMDA/AMPA overactivation triggers toxic cascades

Mitochondrial Dysfunction: Calcium dysregulation impairs energy production

Oxidative Stress: Excitotoxicity generates reactive oxygen species

Apoptosis Pathways: Overactivation triggers neuronal death

Therapeutic Window

Successful therapies would:

Enhance GABAergic inhibition safely
Reduce excitotoxic glutamate signaling
Preserve physiological glutamatergic transmission
Protect against calcium dysregulation

Cross-References

[Alzheimer's Disease - Therapeutic Approaches](/diseases/alzheimers-disease)
[GABA Signaling in Neurodegeneration](/mechanisms/gaba-signaling)
[Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
[Glutamate Transporters](/proteins/eaat2-protein)
[NMDA Receptor Signaling](/mechanisms/nmda-signaling)
[AMPA Receptor Biology](/proteins/ampa-receptor)
[Calcium Dysregulation in AD](/mechanisms/calcium-dysregulation-pathway)

External Links

[PubMed - GABA Modulators AD](https://pubmed.ncbi.nlm.nih.gov/?term=GABA+Alzheimer+modulators)
[PubMed - Excitotoxicity AD](https://pubmed.ncbi.nlm.nih.gov/?term=excitotoxicity+Alzheimer)
[ClinicalTrials.gov - AD Cognitive](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=cognitive)

References

[Sage Therapeutics](https://www.sagerx.com/) (n.d.)

[Supernus Pharmaceuticals](https://www.supernus.com/) (n.d.)

[AstraZeneca](https://www.astrazeneca.com/) (n.d.)

[Daiichi Sankyo](https://www.daiichisankyo.com/) (n.d.)

[Biogen](https://www.biogen.com/) (n.d.)

[Forss, M. et al. GABA-A receptor modulation in Alzheimer's disease (2023)](https://doi.org/10.1016/j.pharmther.2023.108234)

[Liu, J. et al. Glutamate transporter dysfunction in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Green, A.R. et al. NMDA receptor antagonists for neuroprotection in AD (2018)](https://doi.org/10.1016/j.neuropharm.2018.01.012)

[Ward, B.A. et al. AMPA receptor modulators for cognitive enhancement (2019)](https://doi.org/10.1016/j.expneurol.2019.05.008)

📖 View canonical wiki page →